v3.26.1
Equity
 6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Equity Equity
At-the-market offering program 
On August 7, 2025, the Company entered into an EDA pursuant to which it may issue, offer, and sell, from time to time, up to an aggregate gross sales price of $400.0 million of shares of its common stock through an ATM offering program, which includes the ability to enter into FSAs. Since the establishment of the ATM offering program, the Company did not enter into any FSAs related to the EDA. As of June 30, 2026, the Company had capacity to issue up to an aggregate gross sales price of $370.0 million in shares of common stock under the ATM offering program. Details of the Company's ATM offering activity were as follows:
Three Months EndedSix Months Ended
June 30,June 30,
2026202520262025
(In thousands)
Shares issued1,343 — 1,343 — 
Net proceeds$29,644 $— $29,644 $— 
Issuance costs$356 $— $356 $— 

Equity forward sale agreements
On December 5, 2025, the Company completed a follow-on public offering of 10.2 million shares of the Company's common stock at a public offering price of $19.70 per share. In addition, on December 23, 2025, the underwriters exercised their option to purchase 1.5 million additional shares of common stock. Pursuant to the FSAs entered into in connection with the offering, the Company has discretion to settle the FSAs on one or more settlement dates prior to December 6, 2027, subject to certain price adjustments as set forth in the FSAs as well as adjustments for transaction and other associated fees. The FSAs will be physically settled with shares of common stock issued by the Company, unless the Company elects to settle the FSAs in net cash or net shares, subject to certain conditions. If the Company elects to physically settle the FSAs, the Company will physically issue shares of common stock to the banking counterparties at the then-applicable forward sale price and receive proceeds at that time.
In March 2026, the Company partially settled the FSAs with physical delivery of 4.3 million shares of common stock to the counterparties in exchange for cash of $81.3 million. At June 30, 2026, the Company could have settled all of its outstanding FSAs with physical delivery of 7.4 million shares of common stock to the banking counterparties in exchange for cash of approximately $139.6 million. If the FSAs had been net cash or net share settled at June 30, 2026, the Company estimates that the counterparties, in aggregate, would have been entitled to a net settlement of $16.8 million or 792,557 shares, respectively.
The forward price used to determine amounts due at settlement is calculated based on the public offering price, subject to transaction and other associated fees, adjusted by the overnight bank funding rate, less a spread, and less expected dividends on the Company's common stock during the period the FSAs are outstanding.
The FSAs are indexed to the Company's stock and meet the other requirements for equity classification. As a result of the equity classification, no gain or loss is recognized in earnings associated with the subsequent changes in fair value of the FSAs. Stockholders' equity equal to cash proceeds net of deferred issuance costs were and will be recorded upon settlement.
FSAs earnings per share dilution
Prior to settlement, the potentially issuable shares pursuant to the FSAs will be reflected in the Company's diluted earnings per share calculation using the treasury stock method. Share dilution occurs when the average market price of the Company's stock during the reporting period is higher than the then-applicable forward sale price at the end of the reporting period. For more information on earnings per share, see Note 7.